Assisted reproductive technology (ART) has resulted in more than 5 million births worldwide. However, mainstream ART techniques are not always successful for an estimated 30% of infertile patients in whom gametes are nonviable.
INTRODUCTION
Over 5 million babies have been born as a result of assisted reproduction technology (ART) [1] , with an average of 200 000 ART babies born per year [2] . While ART encompasses a suite of sophisticated laboratory interventions, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI; whereby sperm is injected directly into the ooplasm), such technology fails to benefit an estimated 28% of cases in whom idiopathic infertility is diagnosed [3, 4] . A further obstacle occurs when patients are entirely devoid of viable gametes. In those circumstances, the only solution involves adoption or the use of donor gametes. Furthermore, such instances would include ovarian or testicular failure or ageing, genetic disease, or a repeated incidence of poor quality embryos and IVF failure. Given a choice, most patients in such a position would wish for genetic parenthood, which is possible only artificially by incorporation of paternal or maternal DNA into engineered cells that exhibit the molecular and physiological characteristics of natural gametes. However, creation of gametes from diploid primordial germ cells (PGCs) via oogenesis and spermatogenesis requires a series of highly complex molecular and genetic processes. It is these two key processes that researchers aim to simulate in vitro in the creation of in vitroderived, or ''artificial,'' gametes (AGs).
Current efforts to derive such synthetic cells use a specialized cell type that possesses the ability to self-renew and maintain a ''founder'' population, termed stem cells (SCs). Upon cell division in vivo, one daughter cell retains its function as a SC, while the other can differentiate into some or all of the major specialized cell types of tissues or organs. SCs exist in unique microenvironments, referred to as ''niches,'' representing a heterogeneous population of both SCs and surrounding tissue-specific cells, which confer the appropriate molecular and physiological signals to control self-renewal [5] . The role of pluripotent mammalian embryonic SCs (ESCs) in establishing the germline is well established [6] . However, it was only upon the discovery that mouse ESCs (mESCs) can develop into PGCs in vitro, and occasionally form early spermatids or oogonia following further culture, that their potential in the creation of synthetic gametes was first implied [7] [8] [9] .
Two different methods, adopting a variety of modifications, have been used to obtain PGCs from human ESCs (hESCs) and mESCs. The first method consists of spontaneous differentiation in adherent culture following the removal of factors promoting pluripotency [7, [10] [11] [12] . The second method implicates the formation of three-dimensional structures known as embryoid bodies [8, 9, [12] [13] [14] [15] . It would seem that while the adherent culture method appears to stimulate oogenesis, the three-dimensional embryoid body culture method favors spermatogenesis [16] .
Ideally, AGs should be synthetic cells that successfully initiate embryogenesis and create a healthy individual [17] . Considerable research during the last 2 decades has attempted to engineer functional AGs in vitro that resemble and behave as their in vivo counterparts [6, 7, 9, 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] (Table 1) . Several in vitro studies have successfully targeted the very early steps of gamete development [7, 8, 10, 11, 13, 14] or subsequent maturational steps by using gametes that originated in vivo). The most recent example was the work of Sato et al. [22] , who demonstrated in vitro generation of sperm from neonatal mouse testes containing only gonocytes or primitive spermatogonia with serum-free culture medium, resulting in healthy offspring following microinsemination [23] . However, the gametes produced were precursors to mature gametes and would be unlikely to be viable for routine clinical use. Indeed, bridging both stages of development has proven to be far more difficult [11, 23] . Although one group has reported obtaining mice born live from AG sperm, the pups died shortly after birth from defects believed to be related to imprinting problems [10] .
Owing to the potential impact of these developments upon society, such publications describing the creation and use of AGs in a research environment generate significant levels of ''hype'' in the media, often resulting in controversy and skepticism. It is critical to assess the quality of AGs by determining their capacity for fertilization and early embryogenesis [23] to allow these engineered cells to be applied clinically with confidence. Indeed, most current efforts appear to be geared toward the use of AGs to achieve successful fertilization and pregnancy, with scant attention paid to confirmation of molecular integrity and clinical applicability of AGs. Here we discuss a suite of clinical parameters currently used to assess gamete and embryo viability and discuss markers of gamete function that may complement future studies attempting to derive AGs. We also discuss the pros and cons of in vitro AG derivation and discuss the feasibility of this pioneering technology for reproductive medicine.
ARTIFICIAL GAMETES IN REPRODUCTIVE SCIENCE AND MEDICINE
AGs represent powerful tools for elucidating the molecular physiology of gametogenesis and associated mechanisms underlying infertility [24] . Use of AGs could also assist research programs by providing large numbers of gametes at defined time points, reducing numbers of animals required for research, ensuring a more predictable supply than is normally encountered with animal models, and eliminating the need for human donors and the complicated ethical procedures involved. Moreover, the ability to manipulate AGs in vitro to create transgenic animals would be invaluable [10] , representing a rapid alternative to current techniques with the benefit of reduced cost and labor. The ability to generate human gametes (with random or designed genetic modifications) will potentially allow the study of multigenerational human genetics in vitro. Such research may also facilitate generation of ideal ''universal donor'' cells, with appropriate combinations of haplotypes at histocompatibility loci [23] .
Creation of AGs may also provide novel therapeutic options for infertile humans devoid of viable gametes. Presently, 25% of infertile women in the United Kingdom are classified as anovulatory [25] , while 2%-4% of the male population suffers from azoospermia [26, 27] . In these cases, most individuals may be treated by procedures such as surgical sperm retrieval. However, there are still some cases of human infertility where the application of such techniques is not possible. Premature ovarian failure (POF) is a heterogeneous disorder affecting ;1% of women less than 40 years of age and ;0.01% of women by the age of 30 [28] . POF is a primary ovarian defect characterized by primary amenorrhea or premature ovarian follicle depletion before the age of 40 [29] that creates an infertile condition. POF caused by a depletion of ovarian follicles, known as afollicular POF, is impossible to treat without the use of donor oocytes.
Approximately 1% of all men and 10% of infertile men are affected by testicular failure as a result of obstructive azoospermia (OA; blockage within testes, resulting in prevention of sperm ejaculation) or nonobstructive azoospermia (NOA; complete absence of sperm and spermatogenesis within the testes) [30] . The retrieval of mature testicular spermatozoa is possible for men in whom NOA is diagnosed [31] , and testicular sperm extraction (TESE) combined with ICSI offers such men the possibility of having their own genetic children [32] . Furthermore, the success of testicular biopsy techniques varies, with success rates of 16.7%-63.5% depending on the operator and surgical technique used (compared to ;90%-100% in OA patients) [32] [33] [34] [35] [36] . ICSI following TESE is known to yield lower birth rates in cases of NOA than OA (;19% and ;28%, respectively). Additionally, pregnancy failure rates are significantly higher following ICSI using sperm from NOA men (11.5%) than from OA men (2.5%), making the prognosis of fertility in a couple with an NOA male very poor indeed [34, 35, 37] .
Gamete donations in the United Kingdom have been described as being at a ''catastrophic low'' after donor anonymity was abolished in 2005 [38] [39] [40] . The use of AGs would help overcome this shortage while avoiding the exposure of donors to the potential risks and side-effects of gamete harvesting procedures [24] . Above all, there are likely to be psychological benefits for a child born from the use of AGs, as the child would be genetically related to the parents [41] . Another potential use of AGs would be as a resource to train students in embryological techniques such as ICSI or oocyte grading [41] . Presently, training relies heavily upon donated human gametes that are clearly in short and unpredictable supply or gametes harvested from suitable animal models, the supply of which can be unpredictable and that are ultimately not the same as human gametes. It is difficult to predict how patients will respond to the potential use of AGs for their fertility treatment. Clinicians may have concerns that such patients may be desperate to use any such novel treatment offered and may not fully assess the risks, known or unknown, of using AGs. It is likely that such concerns will be allayed only through application of extensive preclinical animal and human studies and identification of suitable biomarkers of normal gamete potential.
ETHICAL CONSIDERATIONS AND LEGAL STATUS FOR THE USE OF AGS
Policies regarding AG derivation and use vary among different countries [42, 43] . In the United Kingdom, research into the derivation of AGs is classified as a high priority by the Human Fertilization and Embryology Authority [44] . However, present legislation states that gametes created in vitro cannot be used in any form of clinical treatment [44] . The situation is more complex in the United States, where legislation pertaining to hESC research varies among states. Currently, the overall stance on AGs in the United States is less clear, with further ethical review required [42, 43, 45] . Japan currently allows derivation of AGs from hESC subject to regulation, but fertilization is prohibited [45] .
The International Society for Stem Cell Research produced the document Guidelines for the Conduct of Human Embryonic Stem Cell Research, specifically designed to have global applications with regard to providing global policy guidelines [45, 46] . However, regulations regarding AGs and their use remain unclear or unaddressed [45] . The success or failure of ongoing research studies will dictate whether existing legislation will be revised in future. It is also likely that legal guidelines regarding SC research may influence the pace at which AG research progresses. The possibility of human AGs being available to the general public may lead to an entirely new way of conceiving children. People who are not infertile may also want access to this technology, such as same-sex couples, single parents, and postmenopausal women, thus requiring further legislative input.
The convergence of AG derivation with other technologies, notably induced pluripotent SCs, may force confrontation with additional challenging situations, including the creation of embryos from fetal tissue, children, or the deceased [23] . Furthermore, genetic modification of the human germline will raise serious moral concerns for some. Such technology may facilitate the production of large quantities of oocytes and embryos for ART, thereby increasing the number of possibilities for embryo selection based upon genetic profile [23] . Such advancements will not only raise concerns about the creation of embryos in excess of clinical need but will also fuel debate about designer babies and which traits, if any, are legitimate targets for selection [23, 47, 48] .
While the potential benefits of AGs are numerous and a tantalizing prospect, it is likely that the successful creation of viable gametes may create more questions than answers, impeding their translation to the clinic. For example, would the option of using artificially derived gametes be open only to couples who present with no gametes or would it be an option open to all? Given the high emotional and monetary costs of ART and the risk of failure [49, 50] , it seems likely that if couples were given an option of using AGs with a high chance of success, then they would choose the least emotionally and financially draining option, if repeated ART treatment were a likelihood. This in turn queries the choice of selection criteria for AGs. For example, if sperm are not motile but expresses all markers used to study viability, would this still be a viable gamete to use? Of course, procedures such as ICSI negate sperm motility and gamete fusion issues but successfully result in fertilization and birth.
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MARKERS OF GAMETE VIABILITY
While most studies deriving AGs in vitro rely heavily upon markers of gametogenesis such as Oct4, SCP3, and Vasa, specific approaches vary among research teams ( Fig. 1 ; Table  2 ), making reliable comparisons difficult and impractical. Furthermore, dispute has arisen over the stage specificity of some markers [51] . While there is a need to identify such markers to prove the viable genesis of AGs, clinical use of any AGs would additionally require normal physiological function and would need to adhere to strict legal and clinical requirements. Consequently, there is a critical need to include the investigation of biomarkers for proteins critical to functionality.
Sperm Viability
Semen analysis represents the cornerstone diagnostic approach to assessing male fertility and evaluates qualitative characteristics such as appearance, pH, viscosity, volume and sperm number, morphology, and motility. Samples are investigated within 1 h of ejaculation and are compared relative to World Health Organization guidelines to identify abnormalities [52] . Additional analyses determine the proportion of sperm exhibiting abnormal morphology of the head (e.g., the shape or presence of vacuoles), neck, mid-piece, and tail. These analyses, however, may not be indicative of potential fertility but rather only identify extreme cases of infertility such as azoospermia (absence of sperm in the ejaculate) or indicate globozoospermia (round-headed, acrosomeless sperm). While there are many well-recognized causes for human male factor infertility, the underlying molecular factors involved are just beginning to be understood in humans [53, 54] . Recently, knock-out and transgenic mouse models have contributed greatly to identification of hundreds of candidate male infertility-associated genes [54] . Proteomic techniques such as two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, and differential in gel electrophoresis have allowed identification of numerous sperm-specific proteins, and further research has increased our current understanding of their involvement in motility, capacitation, acrosome reaction, and fertilization [55] . Such studies also have demonstrated how posttranslational modifications, such as phosphorylation or proteolytic cleavage, bring about physiological changes in sperm function [55] . Comparative proteomic studies have assisted in the identification of proteins of interest in infertile men in comparison to that in fertile men [56] , potentially identifying novel biomarkers of sperm fertility [55] .
A factor which is largely overlooked is the potential role played by seminal plasma in conferring biochemical modifications upon sperm, leading to sperm maturity. Representing 95%-98% of total semen volume in some mammalian species [57, 58] , seminal plasma may play a variety of roles, including modulating sperm function and the ability of sperm to interact with the epithelia and female genital tract secretions [58, 59] . Indeed, several seminal plasma factors have been associated with improvement of sperm fertility within animal models [60] . However, in an era of ART, where certain physiological mechanisms may be circumvented, seminal plasma modifications may not be an absolute necessity for successful fertilization but should not be overlooked.
Multiple criteria must be met by in vitro-derived sperm to be considered clinically viable, including the ability to competently initiate oocyte activation and embryogenesis. Fortunately, many proteins have been identified that may serve as effective indicators of sperm viability. However, fusion of the sperm and oocyte membranes, a critical component of in vivo fertilization, requires a mechanism by which the two gamete lipid bilayers are transformed from two separate barriers into a single lipid bilayer. While this mechanism provides many proteins that may be studied as markers of sperm viability, it is important to note that this mechanism is bypassed during the process of ICSI in the clinic. As the clinical application of artificial sperm will most likely use ICSI to accurately and predictably deliver engineered sperm into the ooplasm, it is necessary to identify markers that are vital to sperm function downstream of sperm-oocyte fusion.
Following fusion, mammalian oocytes undergo activation, a process controlled by intracellular calcium oscillations [61] . This mechanism initiates the release of the oocyte from meiotic arrest, cortical granule exocytosis, progression of the cell cycle, pronuclear formation, maternal mRNA recruitment, and embryonic gene expression [62] [63] [64] . Recent evidence strongly implicates a sperm-specific phospholipase C (PLCf) as the mammalian oocyte activation factor (reviewed by Kashir et al. [4] ). This protein therefore represents a critical marker for the oocyte-activating ability of an artificial sperm cell.
Subsequent to oocyte activation at fertilization, the nucleus delivered by the sperm undergoes remodeling in order to permit DNA replication and fusion with the female pronucleus. The sperm nuclear envelope is removed, and sperm-specific protamines or histones are replaced by histone variants from maternal stores [65] . DNA fragmentation in sperm deemed morphologically normal exerts a negative effect upon embryo quality and is associated with increased risk of pregnancy loss following IVF and ICSI [66] [67] [68] [69] . Consequently, proteins involved in the onset of sperm DNA fragmentation hold significant promise as potential markers for poor viability.
While relatively little is known about such proteins, it is clear that continued screening will resolve a number of sperm proteins necessary for sperm function and thus allow the creation of a panel of marker proteins that can provide crucial information on the suitability of AGs for clinical application. Increasing knowledge will permit the identification of further markers of sperm function, which may be used in such screening studies. Such an example is the role played by various RNA transcripts within sperm. Although RNA transcription is not thought to occur in mature sperm, many mRNA and micro-RNA transcripts persist in human sperm and may possess a functional role following delivery to the oocyte [70, 71] . Indeed, an integral role has been proposed for spermborne micro-RNA-34c within the first cell division of embryogenesis [72] .
Oocyte Viability
Under normal circumstances, oocytes exhibiting aberrant morphology are not used in clinical procedures due to concerns over the developmental potential of the ensuing embryo. If artificially produced oocytes continue to exhibit abnormal morphology, then specific markers of viability would be an absolute necessity in order to select the most viable oocytes for clinical application (reviewed by Li et al. [73] ). The biggest hurdle for accurately assessing the viability of an individual oocyte is to ensure the oocyte is unharmed both during and after analysis. Once multiple oocyte-like cells (OLCs) of consistent quality are produced, whole oocyte gene expression profile analysis will become a powerful screening technique by sacrificing a subset of one or more OLCs as an indicator of the remainder [74, 75] . Until that time, molecular analysis of OLC quality requires a more subtle approach.
Oocyte development is exceptionally complex, involving multiple factors at different stages of follicle development (reviewed by Matzuk and Lamb [54] ). Numerous investigations into the function of molecules generated by the oocyte or follicular cells, using modified genes in transgenic mice, almost always result in deleterious effects on female fertility (reviewed by Barnett et al. [76] ), indicating that these molecules are required for normal development. Conversely, however, a clearly defined panel of markers of oocyte health has still not been established in mice, which have been intensely studied and where tissue is readily available. Wang et al. [77] characterized the proteome of mouse oocytes and zygotes at different developmental stages and provided insight into the requirements of healthy oocytes. An equivalent study of human oocytes will provide a clear benchmark from which a panel of markers essential for normal oocyte development may be established.
Granulosa cells surrounding the oocyte during follicular development subsequently differentiate into cumulus cells, which are removed prior to ICSI, and represent a stock of ARTIFICIAL GAMETES AND REPRODUCTIVE MEDICINE unwanted cells for analysis [78] . Some molecules have been linked with higher quality oocytes, for example, pentraxin 3 (PTX3) [79] , progesterone receptor [80] , hyaluronic acid synthase 2 (HAS2), gremlin1 (GREM1) [81] [82] [83] , BCL2L11 (also known as BIM), phosphoenolpyruvate carboxykinase 1 (PCK1), and nuclear factor IB (NFIB) [84] . Ongoing work investigating the cumulus cell transcriptome is likely to reveal additional markers of oocyte quality (reviewed by Huang and Wells [85] ). Oocyte maturation, a process whereby mammalian oocytes acquire successful activation capability to correctly initiate embryogenesis, involves a series of nuclear and cytoplasmic maturation events [86] [87] [88] . Nuclear maturation involves germinal vesicle breakdown, chromosomal condensation and segregation, and polar body extrusion. Cytoplasmic maturation is less well characterized but involves organelle reorganization, elevations in the content of stored Ca 2þ and antioxidants [89] , and the storage of mRNA and protein [87, 88] .
Mitochondria also play an important and dynamic role in oocyte maturation by supplying ATP [90, 91] and exhibit dynamic changes in both number and cytoplasmic localization [88] . Reduced numbers of mitochondria and consequent reduction in ATP may be critical factors for compromised oocyte quality [91] [92] [93] [94] [95] . Mammalian oocytes typically contain ;100 000 mitochondria, occupying up to 30% of the cytoplasmic space [88, 93, 96] . The ATP content of mature human oocytes is correlated with developmental outcome, and even a transient decrease in ATP during maturation can lead to developmental arrest during cleavage [92] . Oocytes produce a polar body at the first meiotic division in response to preovulatory luteinizing hormone surge [97] , which, as a reflection of the oocyte, can be analyzed to investigate chromosomal and mitochondrial abnormalities [98, 99] . It should be noted that in the United States, analysis of the polar body is limited to the first one, unlike the United Kingdom, where either polar body can be taken for analysis. In future, we may also be able to use the polar body to analyze genes expressed in latter stages of oocyte development, for example, GDF-9 and BMP-15, both of which are required for normal health [100, 101] . Consequently, proteins associated with these critical processes of oocyte maturation may represent useful biomarkers for assessing AG viability.
Culture medium can also be used to assess factors secreted by the oocyte and follicle. Increased activin A levels have been associated with oocyte quality [102] . In culture, higher levels of GDF-9, an oocyte secreted factor, is associated with improved oocyte quality [101, 103] . Glucose metabolism also plays a critical role in oocyte quality (reviewed by SuttonMcDowall et al. [104] ). Consequently, metabolites excreted into culture medium could prove to be useful markers of oocyte viability (reviewed by Revelli et al. [105] ). Modification of oocyte glycoproteins by oocyte-specific deletion of core 1-derived O-glycans leads to an increase in follicle number and litter size in mice [106] . As yet, it is unknown which oocytederived glycoprotein(s) is responsible for this increase in follicle survival. However, this oocyte-generated glycoprotein may well be a marker for enhanced oocyte quality.
It is clear, therefore, that noninvasive techniques already exist to assess specific aspects of oocyte quality. These methods, coupled with increased understanding of potential oocyte viability markers, will prove vital in selecting AGs for downstream application.
Embryo Viability
The oocyte to embryo transition in humans lasts for 3 days, encompassing gamete fusion, migration and fusion of the germ cell pronuclei, genetic and epigenetic reprogramming, and a series of cleavage divisions that culminate with a major wave of embryonic genome activation [107] . Approximately 1800 mRNAs are modulated within this time, with most being downregulated and a small group being up-regulated in the first 2 days of development, followed by an increase in abundance of a large group of mRNAs on day 3 [107, 108] . Current embryo assessment criteria are largely morphological and are based upon cleavage rates. A variety of morphological parameters at each stage of preimplantation embryo development have been associated with increased viability in pronuclear embryos (symmetry, position and location of pronuclei and nucleoli and cytoplasmic morphology); cleavage stage embryos (blastomere number and degree of fragmentation); and blastocysts (blastocoelic cavity expansion, inner cell mass, and trophectoderm development) [109] [110] [111] [112] [113] [114] [115] . More recently, noninvasive strategies have also been explored, including measurement of nutrient levels in culture medium [116] [117] [118] [119] [120] and oxygen consumption; although the current techniques involved can be detrimental to the embryo [121, 122] . Genomic and proteomic profiling has revealed markers such as ubiquitin (involved in implantation and blastocyst development) and soluble human leukocyte antigen-G (involved in embryological maternal immune defense; sHLA-G) [123] [124] [125] [126] [127] .
Most recently, analytical examination of the embryonic metabolome (a spectrum of small-molecule metabolites as biomarkers, representing the functional phenotype in a biological system) has also led to significant advancement in our understanding of noninvasive markers for embryo quality [114, 128, 129] . Indeed, time-lapse imaging indicates that successful development at the blastocyst stage can be predicted as early as the four-cell stage, based on parameters of the first three mitotic divisions including duration of the first cytokinesis, the interval between the end of the first mitosis and the initiation of the second, and the interval between the appearance of the cleavage furrows of the second and third mitoses [130] . Furthermore, assessment of rhythmical cytoplasmic movements in mouse oocytes undergoing activation, using particle image velocimetry, may represent a noninvasive and effective indicator of zygote viability following ART [131, 132] . As successful preimplantation development may now be predicted prior to embryonic genome activation, human embryo development is likely to be influenced by the inheritance of parental gamete factors [107] . It is therefore critical that the relative status of such factors is considered within artificially derived gametes.
Although embryo assessment protocols consider morphology and cleavage rates, many embryos that meet these criteria do not implant, or they spontaneously abort during pregnancy [133, 134] . While the underlying causes remain unknown, it is recognized that embryo aneuploidy (numerical chromosomal abnormalities), which appears with high frequency in human oocytes and embryos, may play a key role [135] [136] [137] [138] [139] [140] [141] [142] [143] . Indeed, the number and distribution of the MLH1 mismatch repair protein marked regions of recombination, while the crossover configurations in human fetal oocytes may be associated with an increased vulnerability of oocytes to nondisjunction and ultimately to aneuploidy [107, 144] , indicating that such factors may have a crucial role in determining successful embryogenesis. Analysis of single blastomeres by using molecular cytogenetic techniques, such as fluorescence in situ hybridization and comparative genomic hybridization have proved to be powerful tools for analyzing chromosomes from cleavage stage embryos or blastocysts [135, 136] , leading to the identification of the most viable embryos for transfer [145] [146] [147] [148] [149] [150] [151] [152] .
KASHIR ET AL.
The viability and growth of human embryos may inversely correlate with metabolism of growth factors. Indeed, the ''quiet embryo hypothesis'' proposes that hyperactive metabolism occurs in embryos as a result of culture stress [107, 121, 153, 154] . In addition, cell survival may be regulated by specific growth factors, such as insulin-like growth factor 1 and granulocyte-macrophage colony-stimulating factor or CSF2 [107, [155] [156] [157] [158] [159] [160] . However, a further concern is species specificity within different models of development when attempting to identify markers of human embryo health. Indeed, differences have been observed in the expression of OCT4, CDX2 (a caudal-related homeodomain protein), the zinc finger proteins GATA4 and GATA6, and the SOX protein SOX17, among species in mammalian preimplantation development [107, [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] . Indeed, a comprehensive temporal and spatial analysis of protein localization throughout human preimplantation development is still lacking and needs to be fully understood before such knowledge may be applied to AGs [107] .
Consequently, while a plethora of markers and techniques exist for the assessment of gamete and embryo viability, these remain experimental and, in some cases, controversial. However, these may represent efficient methods to study the viability of artificially derived gametes and resultant embryos. Indeed, improvements in culture conditions for human preimplantation embryos now mimic endogenous factors present during embryo migration within the maternal fallopian environment [107, [171] [172] [173] [174] . It is essential that such advances are incorporated into the derivation and assessment of AGs and are taken into account before deciding whether embryos resulting from such synthetic cells are comparable to those produced following ART.
EPIGENETICS AND AGS
Currently the predominant safety concerns over the clinical use of AGs are abnormal chromosomal segregation and genomic imprinting. Some ART techniques are already associated with at least some degree of potential health risk to future offspring. For example, ICSI has been implicated in causing de novo mutations due to the invasive nature of the technique [175] . There is some evidence to suggest that children conceived as a result of ART may be at increased risk of imprinting disorders such as Beckwith-Wiedmann, Angelman, and Silver-Russell syndromes. Furthermore, several studies now suggest that epigenetic alterations at imprinted loci occur during in vitro manipulation of gametes following both IVF and ICSI [176] [177] [178] . In mammals, particular genes are expressed exclusively from chromosomes of maternal or paternal origin [179] . Imprints such as these are normally established during gametogenesis by differential methylation [180] in sperm or oocytes but not both [179] .
Following fertilization, the paternal and maternal genomes undergo rapid and slow demethylation, respectively [181, 182] , and a wave of de novo methylation establishes a specific pattern to the new individual at implantation [21, 183, 184] . Both sperm and oocyte nuclei are sequestered in the zygote but do not unite until the first mitotic division. This results in marked asymmetry between paternal and maternal chromatin prior to the two-cell stage, with the paternal genome being more euchromatic in nature than its female counterpart. However, imprinted gene detection in gametes suggests that selected epigenetic information can be transmitted through the zygote to the two-cell stage without any alterations [179] . The few studies that have analyzed the imprinting status of AGs collectively suggest that gamete derivation using ESCs may cause disruption of genomic imprinting [8, 10, [185] [186] [187] [188] . However, while hESCs appear to exhibit higher epigenetic stability [189] , the limited number of imprinting loci tested thus far show at least partial erasure of previous methylation imprints [8, 10, 187, 188, 190, 191] . It is therefore important that a greater number of imprinted loci are tested at predefined intervals, so that we can better determine the potential for their erasure in AGs. In addition, the ability of ESC-derived gametes to reset sex-specific imprints determining the successful development of offspring has yet to be investigated.
Consequently, epigenetic alterations represent one of the biggest obstacles in the production of clinical grade AGs. Nevertheless, Kono et al. [192] created a viable and fertile parthenogenetic mouse derived from two maternal haploid chromosomal sets, indicating that further research and improved epigenetic manipulation in animal models are indeed able to rectify epigenetic problems. Continued study of a variety of ESCs is required to fully understand the range of epigenomic variability and to identify possible factors that enable complete reprogramming.
CONCLUSIONS
Creation of in vitro-derived gametes is likely to be of great benefit to both reproductive science and the clinical treatment of infertility in patients devoid of viable gametes. While controversial and requiring dedicated legislation, there are clear benefits to the future use of AGs. Although the scientific knowledge needed to achieve in vitro embryonic SC-derived replication of normal germ cell differentiation exists, such methodology remains in its infancy. However, estimates suggest that such cells could be in clinical use in just 5-15 years [193] . It is therefore imperative that scientific progress in this field is comprehensively evaluated and regulated, particularly in terms of the potential risks and benefits of clinical application.
